Update

On April 26, 2013, Health Canada published a notice to inform clinical trial sponsors that information about Clinical Trial Applications ("CTAs") will be published.

The publication of information applies to authorized CTAs that were issued a No-Objection Letter after April 1, 2013. The following information about the clinical trial will be published in Health Canada's clinical trial database:

  • Protocol number;
  • Protocol title;
  • Drug name;
  • Medical condition;
  • Study population;
  • Authorization date;
  • Sponsor name;
  • Health Canada control number; and
  • Start and end date of the clinical trial.

Health Canada's clinical trials database makes clinical trial application information publicly available through Health Canada's website. The database is publicly accessible and will serve as a central index of information that will include information on phase I, II and II drug and biologics clinical trials. The database will not include medical devices or natural health products when it is launched.

The clinical trials database will be implemented by Health Canada in May 2013.

Going forward, sponsors may wish to amend their clinical trial application and informed consent templates to include reference to the Health Canada database. This initiative is yet another measure to increase transparency within Health Canada's regulatory process. Increasing accessibility to clinical trial information may improve efficiency in research. Moreover, the increased public knowledge of on-going clinical trials in Canada may increase study subject engagement and recruitment in clinical trials.

Link to Health Canada's website:

Registration and Disclosure of Clinical Trial Information

Norton Rose Group

Norton Rose Group is a leading international legal practice. We offer a full business law service to many of the world's pre-eminent financial institutions and corporations from offices in Europe, Asia, Australia, Canada, Africa, the Middle East, Latin America and Central Asia.

Knowing how our clients' businesses work and understanding what drives their industries is fundamental to us. Our lawyers share industry knowledge and sector expertise across borders, enabling us to support our clients anywhere in the world. We are strong in financial institutions; energy; infrastructure, mining and commodities; transport; technology and innovation; and pharmaceuticals and life sciences.

We have more than 2900 lawyers operating from 43 offices in Abu Dhabi, Almaty, Amsterdam, Athens, Bahrain, Bangkok, Beijing, Bogotá, Brisbane, Brussels, Calgary, Canberra, Cape Town, Caracas, Casablanca, Dubai, Durban, Frankfurt, Hamburg, Hong Kong, Johannesburg, London, Melbourne, Milan, Montréal, Moscow, Munich, Ottawa, Paris, Perth, Piraeus, Prague, Québec, Rome, Shanghai, Singapore, Sydney, Tokyo, Toronto and Warsaw; and from associate offices in Dar es Salaam, Ho Chi Minh City and Jakarta.

Norton Rose Group comprises Norton Rose LLP, Norton Rose Australia, Norton Rose Canada LLP, Norton Rose South Africa (incorporated as Deneys Reitz Inc), and their respective affiliates.

On January 1, 2012, Macleod Dixon joined Norton Rose Group adding strength and depth in Canada, Latin America and around the world. For more information please visit nortonrose.com.

Norton Rose will join forces with Fulbright & Jaworski L.L.P on June 1, 2013, creating Norton Rose Fulbright a global legal practice with significant depth of expertise across the USA, Europe, Asia, Australia, Canada, Africa, the Middle East, Latin America and Central Asia.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.